Purpose The purpose of this paper will be to analyze if the United States’ health care system and social structures would allow for therapeutic genetic editing to be morally permissible.
Objectives If therapeutic genetic editing cannot be accessed equally by all patients, then the long-term effects of such technology could widen current social inequities in the United States. It would be immoral to practice genetic editing if it contributes to the oppression of individuals. Thus, for genetic editing to be morally permissible it must be equally accessible to all individuals regardless of their income status, race, gender, ect.
Discussion This paper will first explain how unequal access to therapeutic genetic editing technologies can increase the severity of current social inequities. Then, it will look to what institutions need to be in place to prevent oppression that can stem from social structures and genomes. Finally, will then analyze current health disparities and social inequities to understand how equally therapeutic genetic editing technologies could be accessed.
Conclusion The extent of health disparities and social inequity do not allow for genetic editing technologies to be morally permissible in the United States.
- Paper Presentation
- philosophy, biomedical ethics, health care
Most discussions on the morality of genetic editing technologies focus on whether or not their initial use is morally permissible on an individual patient. I will focus on whether or not the potential future distribution of therapeutic genetic editing would be permissible in the United States.